HIV epidemic in Asia: Optimizing and expanding vaccine development

Expert Review of Vaccines

Volumn 11, Issue 7, 2012, Pages 805-819

  Nitayaphan, Sorachai ^a   Ngauy, Viseth ^a   O'Connell, Robert ^b   Excler, Jean Louis ^c  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b US Military HIV Research Program (MHRP)   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Asia; efficacy trial; HIV; prime boost; vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS DNA;

ASIA; AUSTRALIA; B LYMPHOCYTE; CHINA; CYTOTOXICITY; DRUG DEVELOPMENT; DRUG EFFICACY; EPIDEMIC; HEALTH CARE; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; INDIA; JAPAN; MACACA; MEDICAL EDUCATION; NONHUMAN; PARAINFLUENZA VIRUS 1; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTITUTION; REVIEW; SEXUAL TRANSMISSION; T LYMPHOCYTE; THAILAND; TRANSLATIONAL RESEARCH; VACCINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ASIA; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNSAFE SEX; VACCINATION; VACCINES;

EID: 84865404106     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.49     Document Type: Review

References (160)

1. Srikantiah P, Ghidinelli M, Bachani D et al. Scale-up of national antiretroviral therapy programs: Progress and challenges in the Asia Pacific region. AIDS 24(Suppl. 3), S62-S71 (2010).
2. Granich R, Crowley S, Vitoria M et al. Highly active antiretroviral treatment as prevention of HIV transmission: Review of scientific evidence and update. Curr. Opin. HIV AIDS 5(4), 298-304 (2010). Excellent review of the challenges of antiretroviral treatment for prevention.
3. Lo YR, Nguyen TTT, Srikantiah P et al. AIDS in Asia and the Pacific. In: HIV/ AIDS in the Post-HAART Era: Manifestations, Treatment, and Epidemiology. Hall JC, Hall BJ, Cockerell CJ (Eds). People's Medical Publishing House, CT, USA, 839-864 (2011). Extensive and excellent review of the HIV epidemic in Asia.
4. UNAIDS. Global HIV/AIDS Response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011.
5. Cáceres CF, Konda K, Segura ER et al. Epidemiology of male same-sex behaviour and associated sexual health indicators in low-and middle-income countries: 2003-2007 estimates. Sex. Transm. Infect. 84(Suppl. 1), i49-i56. (2008).
6. Morineau G, Nugrahini N, Riono P et al. Sexual risk taking, STI and HIV prevalence among men who have sex with men in six Indonesian cities. AIDS Behav. 15(5), 1033-1044 (2011).
7. Kanter J, Koh C, Razali K et al. Risk behaviour and HIV prevalence among men who have sex with men in a multiethnic society: A venue-based study in Kuala Lumpur, Malaysia. Int. J. STD AIDS 22(1), 30-37 (2011).
8. Sheridan S, Phimphachanh C, Chanlivong N et al. HIV prevalence and risk behaviour among men who have sex with men in Vientiane Capital, Lao People's Democratic Republic, 2007. AIDS 23(3), 409-414 (2009).
9. Setia MS, Brassard P, Jerajani HR et al. Men who have sex with men in India: A systematic review of the literature. J. LGBT Health Res. 4(2-3), 51-70 (2008).
10. Brahmam GN, Kodavalla V, Rajkumar H et al.; IBBA Study Team. Sexual practices, HIV and sexually transmitted infections among self-identified men who have sex with men in four high HIV prevalence states of India. AIDS 22(Suppl. 5), S45-S57 (2008).
11. de Lind van Wijngaarden JW, Brown T, Girault P, Sarkar S, van Griensven F. The epidemiology of human immunodeficiency virus infection, sexually transmitted infections, and associated risk behaviors among men who have sex with men in the Mekong Subregion and China: Implications for policy and programming. Sex. Transm. Dis. 36(5), 319-324 (2009). Excellent review of the HIV epidemic in sex with men in Asia.
12. He Q, Peng WJ, Zhang JQ, Wang BX, Wang J. Prevalence of unprotected anal intercourse and unprotected vaginal intercourse among HIV-positive men who have sex with men in China: A metaanalysis. Sex. Transm. Infect. 88(3), 229-233 (2012).
13. Chow EP, Wilson DP, Zhang J, Jing J, Zhang L. Human immunodeficiency virus prevalence is increasing among men who have sex with men in China: Findings from a review and meta-analysis. Sex. Transm. Dis. 38(9), 845-857 (2011).
14. Yun K, Xu JJ, Reilly KH et al. Prevalence of bisexual behaviour among bridge population of men who have sex with men in China: A meta-analysis of observational studies. Sex. Transm. Infect. 87(7), 563-570 (2011).
15. Yu BN, Wang XA, Yu Y et al. An exploratory survey of male sex workers and HIV risk in an urban area of Southwest China. Sex. Transm. Infect. 87(Suppl. 1), A67-A68 (2011).
16. Guadamuz TE, Wimonsate W, Varangrat A et al. HIV prevalence, risk behavior, hormone use and surgical history among transgender persons in Thailand. AIDS Behav. 15(3), 650-658 (2011).
17. Johnson WD, Diaz RM, Flanders WD et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst. Rev. 3, CD001230 (2008).
18. Hart GJ, Elford J. Sexual risk behaviour of men who have sex with men: Emerging patterns and new challenges. Curr. Opin. Infect. Dis. 23(1), 39-44 (2010).
19. Chemnasiri T, Netwong T, Visarutratana S et al. Inconsistent condom use among young men who have sex with men, male sex workers, and transgenders in Thailand. AIDS Educ. Prev. 22(2), 100-109 (2010).
20. McDaid LM, Hart GJ. Sexual risk behaviour for transmission of HIV in men who have sex with men: Recent findings and potential interventions. Curr. Opin. HIV AIDS 5(4), 311-315 (2010).
21. Grant RM, Lama JR, Anderson PL et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587-2599 (2010). Efficacy of pre-exposure chemoprophylaxis in men who have sex with men (MSM), including in Thailand.
22. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk US populations: Current considerations in light of new findings. AIDS Patient Care STDS 25(2), 63-71 (2011).
23. van Griensven F, Thienkrua W, Sukwicha W et al. Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: Implications for preand post-exposure prophylaxis against HIV infection. J. Int. AIDS Soc. 13, 13 (2010).
24. Mathers BM, Degenhardt L, Phillips B et al.; 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 372(9651), 1733-1745 (2008).
25. Lindan CP, Lieu TX, Giang LT et al. Rising HIV infection rates in Ho Chi Minh City herald emerging AIDS epidemic in Vietnam. AIDS 11(Suppl. 1), S5-S13 (1997). (Pubitemid 27460088)
26. Quan VM, Chung A, Long HT, Dondero TJ. HIV in Vietnam: The evolving epidemic and the prevention response, 1996 through 1999. J. Acquir. Immune Defic. Syndr. 25(4), 360-369 (2000). (Pubitemid 32107168)
27. Hammett TM, Van NT, Kling R, Binh KT, Oanh KT. Female sexual partners of injection drug users in Vietnam: An at-risk population in urgent need of HIV prevention services. AIDS Care 22(12), 1466-1472 (2010).
28. Poon AN, Li Z, Wang N, Hong Y. Review of HIV and other sexually transmitted infections among female sex workers in China. AIDS Care 23(Suppl. 1), 5-25 (2011).
29. Chandeying V. Epidemiology of HIV and sexually transmitted infections in Thailand. Sex. Health 1(4), 209-216 (2004).
30. Zhang KL, Ma SJ, Xia DY. Epidemiology of HIV and sexually transmitted infections in China. Sex. Health 1(1), 39-46 (2004).
31. Moses S, Ramesh BM, Nagelkerke NJ et al. Impact of an intensive HIV prevention programme for female sex workers on HIV prevalence among antenatal clinic attenders in Karnataka state, south India: An ecological analysis. AIDS 22(Suppl. 5), S101-S108 (2008).
32. Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25(5), 679-689 (2011). Reference paper for the description of the molecular epidemiology of HIV worldwide and breakdown per subgeographical regions.
33. Takebe Y, Liao H, Hase S et al. Reconstructing the epidemic history of HIV-1 circulating recombinant forms CRF07-BC and CRF08-BC in East Asia: The relevance of genetic diversity and phylodynamics for vaccine strategies. Vaccine 28(Suppl. 2), B39-B44 (2010).
34. Weniger BG, Limpakarnjanarat K, Ungchusak K et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 5(Suppl. 2), S71-S85 (1991).
35. Park LS, Siraprapasiri T, Peerapatanapokin W, Manne J, Niccolai L, Kunanusont C. HIV transmission rates in Thailand: Evidence of HIV prevention and transmission decline. J. Acquir. Immune Defic. Syndr. 54(4), 430-436 (2010).
36. Ainsworth M, Beyrer C, Soucat A. AIDS and public policy: The lessons and challenges of 'success' in Thailand. Health Policy 64(1), 13-37 (2003). (Pubitemid 36315760)
37. Tabprasit S, Kana K, Sununtarod E et al. Recent trends in estimated HIV-1 incidence among Royal Thai Army (RTA) conscripts from 2005-2009 in Thailand. Presented at: 18th International AIDS Conference. Vienna, Austria, 18-23 July 2010.
38. van Griensven F, Varangrat A, Wimonsate W et al. Trends in HIV Prevalence, estimated HIV incidence, and risk behavior among men who have sex with men in Bangkok, Thailand, 2003-2007. J. Acquir. Immune Defic. Syndr. 53(2), 234-239 (2010).
39. Wirachsilp P, Kantakamalakul W, Foongladda S et al. Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J. Trop. Med. Public Health 38(5), 814-827 (2007).
40. Arroyo MA, Phanuphak N, Krasaesub S et al. HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res. Hum. Retroviruses 26(1), 5-12 (2010).
41. Rolland M. Sequence Analysis of HIV-1 Breakthrough Infections in the RV144. Trial. Presented at: AIDS Vaccine 2011. Bangkok, Thailand, 12-15 September 2011.
42. Beyrer C, Baral SD, Walker D, Wirtz AL, Johns B, Sifakis F. The expanding epidemics of HIV type 1 among men who have sex with men in low-and middleincome countries: Diversity and consistency. Epidemiol. Rev. 32(1), 137-151 (2010). Review of the characteristics of the HIV epidemic in MSM in low-and middleincome countries.
43. Kladsawas K, van Griensven F, Wimonsate W et al. Trends in HIV prevalence and risk behavior among men who have sex with men (MSM) in Bangkok, Thailand, 2003 to 2009. Presented at: 18th International AIDS Conference. Vienna, Austria, 18-23 July 2010.
44. van Griensven F, de Lind van Wijngaarden JW. A review of the epidemiology of HIV infection and prevention responses among MSM in Asia. AIDS 24(Suppl. 3), S30-S40 (2010). Excellent review of the HIV epidemic in MSM in Asia.
45. Chariyalertsak S, Kosachunhanan N, Saokhieo P et al. HIV incidence, risk factors, and motivation for biomedical intervention among gay, bisexual men, and transgender persons in Northern Thailand. PLoS ONE 6(9), e24295 (2011).
46. van Griensven F, Thienkrua W, McNicholl J et al. Three years of follow-up in the Bangkok MSM cohort study: Evidence of an explosive epidemics of HIV infection. Presented at: 18th International AIDS Conference. Vienna, Austria, 18-23 July 2010.
47. McNicholl J, Sirivongrangson P, Sinthuwattanawiboon C et al. Prevalence of sexually transmitted infections (STI) in a cohort study of men who have sex with men (MSM) in Bangkok, Thailand. Presented at: The Fourth IAS Conference on HIV Pathogenesis of HIV, Treatment and Prevention. Sydney, VIC, Australia, 22-25 July 2007.
48. Eller L, Eller M, Eser A et al. Lymphocyte dynamics in acute HIV-1 infection: RV217-the early capture HIV cohort study (ECHO). Presented at: AIDS Vaccine 2011. Bangkok, Thailand, 12-15 September 2011. AIDS Res. Hum. Retroviruses 27(10), A-11-A-12 (2011).
49. London AS, Van Landingham MJ, Grandjean N. Socio-demographic correlates, HIV/AIDS-related cofactors, and measures of same-sex sexual behaviour among northern Thai male soldiers. Health Transit. Rev. 7(1), 33-60 (1997).
50. Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: Evolution and challenges. Vaccine 28(Suppl. 2), B45-B49 (2010).
51. Pitisuttithum P. HIV vaccine research in Thailand: Lessons learned. Expert Rev. Vaccines 7(3), 311-317 (2008). (Pubitemid 351520019)
52. Phanuphak P, Teeratakulpixarn S, Sarangbin S et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac. J. Allergy Immunol. 15(1), 41-48 (1997). (Pubitemid 27356812)
53. Pitisuttithum P, Gilbert P, Gurwith M et al.; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebocontrolled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661-1671 (2006). First HIV vaccine Phase III trial in Asia. (Pubitemid 44901996)
54. de Bruyn G, Rossini AJ, Chiu YL et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22(5-6), 704-713 (2004). (Pubitemid 38114901)
55. Nitayaphan S, Pitisuttithum P, Karnasuta C et al.; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190(4), 702-706 (2004). (Pubitemid 39049999)
56. Pitisuttithum P, Berman PW, Phonrat B et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 37(1), 1160-1165 (2004). (Pubitemid 39166651)
57. Karnasuta C, Paris RM, Cox JH et al.; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a Phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23(19), 2522-2529 (2005). (Pubitemid 40332524)
58. Thongcharoen P, Suriyanon V, Paris RM et al.; for the Thai AIDS Vaccine Evaluation Group. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defic. Syndr. 46(1), 48-55 (2007). (Pubitemid 47507433)
59. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS ONE 6(12), e27837 (2011).
60. Ministry of Public Health-Thai AIDS Vaccine Evaluation Group. Screening and evaluation of potential volunteers for a Phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29(25), 4285-4292 (2011).
61. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009). Major Phase III trial showing for the first time vaccine efficacy against HIV acquisition.
62. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275-1286 (2012).
63. O'Hagan JJ, Hernán MA, Walensky RP, Lipsitch M. Apparent declining efficacy in randomized trials: Examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS 26(2), 123-126 (2012).
64. Vaccari M, Poonam P, Franchini G. Phase III HIV vaccine trial in Thailand: A step toward a protective vaccine for HIV. Expert Rev. Vaccines 9(9), 997-1005 (2010).
65. Currier JR, Ngauy V, de Souza MS et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS ONE 5(11), e13983 (2010).
66. Hemachandra A, Puls RL, Sirivichayakul S et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized Phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum. Vaccin. 6(10), 835-840 (2010).
67. Nicholson O, Dicandilo F, Kublin J et al. Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide Phase 1 study of healthy adults. AIDS Res. Hum. Retroviruses, 27(5), 557-567 (2011).
68. Kalams SA, Parker S, Jin X et al.; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS ONE 7(1), e29231 (2012).
69. Barouch DH, O'Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16(3), 319-323 (2010). Demonstration that vaccines with mosaic inserts augment the breadth and depth of cell-mediated immune responses.
70. Sirivichayakul S, Felber B, Kulkarni V et al. Pre-clinical immunogenicity of mosaic Asian AE/B HIV-1 DNA vaccine in mice. Retrovirology 6(Suppl. 3), P321 (2009). National AIDS Control Organization, Ministry of Health & Family Welfare, Government of India. New Delhi: Department of AIDS Control. Annual report 2009-2010 (2011).
71. Mehendale SM, Rodrigues JJ, Brookmeyer RS et al. Incidence and predictors of human immunodeficiency virus type 1 seroconversion in patients attending sexually transmitted disease clinics in India. J. Infect. Dis. 172(6), 1486-1491 (1995).
72. Mehendale SM, Shepherd ME, Divekar AD et al. Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Indian J. Med. Res. 104, 327-335 (1996).
73. Gangakhedkar RR, Bentley ME, Divekar AD et al. Spread of HIV infection in married monogamous women in India. JAMA 278(23), 2090-2092 (1997). (Pubitemid 28016232)
74. Bollinger RC, Brookmeyer RS, Mehendale SM et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 278(23), 2085-2089 (1997). (Pubitemid 28016231)
75. Kumta S, Lurie M, Weitzen S et al. Bisexuality, sexual risk taking, and HIV prevalence among men who have sex with men accessing voluntary counseling and testing services in Mumbai, India. J. Acquir. Immune Defic. Syndr. 53(2), 227-233 (2010).
76. Sahastrabuddhe S, Gupta A, Stuart E et al. Sexually transmitted infections and risk behaviors among transgender persons (Hijras) of Pune, India. J. Acquir. Immune Defic. Syndr. 59(1), 72-78 (2012).
77. Thomas B, Mimiaga MJ, Kumar S, Swaminathan S, Safren SA, Mayer KH. HIV in Indian MSM: Reasons for a concentrated epidemic & strategies for prevention. Indian J. Med. Res. 134(6), 920-929 (2011).
78. Sahni AK, Prasad VV, Seth P. Genomic diversity of human immunodeficiency virus type-1 in India. Int. J. STD AIDS 13(2), 115-118 (2002). (Pubitemid 34135477)
79. Khan IF, Vajpayee M, Prasad VV, Seth P. Genetic diversity of HIV type 1 subtype C env gene sequences from India. AIDS Res. Hum. Retroviruses 23(7), 934-940 (2007). (Pubitemid 47267502)
80. Rodriguez MA, Ding M, Ratner D et al. High replication fitness and transmission efficiency of HIV-1 subtype C from India: Implications for subtype C predominance. Virology 385(2), 416-424 (2009).
81. Neogi U, Sood V, Ronsard L et al. Genetic architecture of HIV-1 genes circulating in north India & their functional implications. Indian J. Med. Res. 134(6), 769-778 (2011).
82. Lakhashe S, Tripathy S, Paranjape R, Bhattacharya J. Evidence of a novel B/C recombinant exhibiting unique breakpoints of near full-length HIV type 1 genome from Northeastern India. AIDS Res. Hum. Retroviruses 24(2), 229-234 (2008). (Pubitemid 351282112)
83. Excler JL, Kochhar S, Kapoor S et al. Preparedness for AIDS vaccine trials in India. Indian J. Med. Res. 127(6), 531-538 (2008).
84. Mehendale S, van Lunzen J, Clumeck N et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res. Hum. Retroviruses 24(6), 873-880 (2008). (Pubitemid 351871679)
85. Mehendale S, Sahay S, Thakar M et al. Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Indian J. Med. Res. 132, 168-175 (2010).
86. Ramanathan VD, Kumar M, Mahalingam J et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses 25(11), 1107-1116 (2009).
87. Vasan S, Schlesinger SJ, Chen Z et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS ONE 5(1), e8816 (2010).
88. Mehendale SM, Thakar M, Sahay S et al. Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Trial in India. Presented at: AIDS Vaccine 2011. Bangkok, Thailand, 12-15 September 2011.
89. Bhattacharyya S, Rajan RE, Swarupa Y et al. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. J. Biol. Chem. 285(35), 27100-27110 (2010).
90. Wu Z, Wang Y, Detels R et al. China AIDS policy implementation: Reversing the HIV/ AIDS epidemic by 2015. Int. J. Epidemiol. 39(Suppl. 2), ii1-ii3 (2010).
91. Qiu Z, Xing H, Wei M et al. Characterization of five nearly full-length genomes of early HIV type 1 strains in Ruili city: Implications for the genesis of CRF07-BC and CRF08-BC circulating in China. AIDS Res. Hum. Retroviruses 21(12), 1051-1056 (2005). (Pubitemid 43069189)
92. Tee KK, Pybus OG, Li XJ et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08-BC and 07-BC in Asia. J. Virol. 82(18), 9206-9215 (2008).
93. Ma L, Guo Y, Yuan L et al. Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07-BC strains circulating in the Xinjiang Province of China. Retrovirology 6, 45 (2009).
94. Chen L, Yang S, Li J et al. Near full-length genomic characterization of a novel HIV type 1 CRF07-BC/CRF08-BC recombinant strain from Yunnan, China. AIDS Res. Hum. Retroviruses 27(6), 693-699 (2011).
95. Ye JR, Yu SQ, Lu HY, Wang WS, Xin RL, Zeng Y. Genetic diversity of HIV type 1 isolated from newly diagnosed subjects (2006-2007) in Beijing, China. AIDS Res. Hum. Retroviruses 28(1), 119-123 (2012).
96. Liu S, Xing H, He X et al. Dynamic analysis of genetic diversity of gag and env regions of HIV-1 CRF07-BC recombinant in intravenous drug users in Xinjiang Uvghur Autonomous Region, China. Arch. Virol. 153(7), 1233-1240 (2008).
97. Zhang Y, Lu L, Ba L et al. Dominance of HIV-1 subtype CRF01-AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med. 3(11), e443 (2006).
98. Li L, Liang S, Chen L et al. Genetic characterization of 13 subtype CRF01-AE near full-length genomes in Guangxi, China. AIDS Res. Hum. Retroviruses 26(6), 699-704 (2010).
99. Teng T, Shao Y. Scientific approaches to AIDS prevention and control in China. Adv. Dent. Res. 23(1), 10-12 (2011).
100. Chen S, Lai C, Wu X et al. Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: A nonhuman primate AIDS model. PLoS One 6(8), e23177 (2011).
101. Liu Q, Li Y, Yang G, Dai J, Ruprecht RM, Shao Y. Molecularly cloned SHIVCN97001: A replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate. J. Med. Primatol. 40(6), 427-436 (2011).
102. Li D, Forrest BD, Li Z et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac. J. Allergy Immunol. 15(2), 105-113 (1997). (Pubitemid 27462567)
103. Zhou X, Liu B, Yu X et al. Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. Eur. J. Pharm. Biopharm. 68(3), 589-595 (2008). (Pubitemid 351318217)
104. Shao Y, Li T, Liu Y et al. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in Phase I clinical trial. Presented at: AIDS Vaccine 2010. Atlanta GA, USA, 28 September-1 October 2010. AIDS Res. Hum. Retroviruses 26(10), A-1-A-184 (2010).
105. Wang S, Liu Y, Li S et al. Listeria prime/ vaccinia boost vaccination strategy elicit robust gag-specific CD8+ CTL responses in BALB/c mice. Presented at: AIDS Vaccine 2010. Atlanta GA, USA, 28 September-1 October 2010. AIDS Res. Hum. Retroviruses, 26(10), A-1-A-184 (2010).
106. Liu L, Wan Y, Wu L et al. Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine. Retrovirology 7, 71 (2010).
107. Dai K, Liu Y, Liu M et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 26(39), 5062-5071 (2008).
108. Meng Q, Lin Y, Ma J et al. A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies. Arch. Virol. 156(8), 1455-1462 (2011).
109. Excler JL, Parks CL, Ackland J, Rees H, Gust ID, Koff WC. Replicating viral vectors as HIV vaccines: Summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 38(4), 511-521 (2010).
110. Huang X, Lu B, Yu W et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 4(1), e4180 (2009).
111. Lu B, Yu W, Huang X, Wang H, Liu L, Chen Z. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replicationcompetent smallpox vaccine: Vaccinia Tiantan strain. J. Biomed. Biotechnol. 970424, 1-9 (2011).
112. Yu S, Feng X, Shu T et al. Potent specific immune responses induced by prime-boostboost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 26(48), 6124-6131 (2008).
113. Yu S, Feng X, Shu T et al. Comparison of the expression and immunogenicity of wild-type and sequence-modified HIV-1 gag genes in a recombinant Sendai virus vector. Curr. HIV Res. 8(3), 199-206 (2010).
114. Zhang X, Wang X, Zhao D et al. Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine. Sci. China. Life Sci. 54(11), 1042-1047 (2011).
115. Yuan T, Li J, Zhang Y et al. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development. Vaccine 29(40), 6903-6910 (2011).
116. Zhang C, Wan Y, Shi J et al. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade. AIDS Res. Hum. Retroviruses 26(5), 569-575 (2010).
117. Wang J, Tong P, Lu L et al. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One 6(3), e18233 (2011).
118. Song Y, Zhang LS, Wang H, Jin H, Li Ch, Jin N. Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105. Acta Virol. 54(4), 293-296 (2010).
119. Liu Y, Li F, Liu Y et al. HIV fragment gag vaccine induces broader T cell response in mice. Vaccine 29(14), 2582-2589 (2011).
120. Sun C, Zhang Y, Liu Y, Zhang M, Chen L. Short communication: Enhancement of immunogenicity of replication-defective adenovirus-based human immunodeficiency virus vaccines in rhesus monkeys. AIDS Res. Hum. Retroviruses 27(6), 681-686 (2011).
121. Zhang Y, Shan H, Trizzino J et al. HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int. J. Infect. Dis. 11(4), 318-323 (2007). (Pubitemid 46992835)
122. Duan S, Shen S, Bulterys M et al. Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan: A hard hit area along a major drug trafficking route. BMC Public Health 10, 180 (2010).
123. Ruan Y, Qin G, Liu S et al. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J. Acquir. Immune Defic. Syndr. 39(4), 459-463 (2005). (Pubitemid 41003793)
124. Li Q, Luo F, Zhou Z et al. Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men. Vaccine 28(29), 4638-4643 (2010).
125. Fujisaki S, Ibe S, Hattori J et al. An 11-year surveillance of HIV Type 1 subtypes in Nagoya, Japan. AIDS Res. Hum. Retroviruses 25(1), 15-21 (2009).
126. Ichikawa S, Kaneko N, Koerner J, Shiono S, Shingae A, Ito T. Survey investigating homosexual behaviour among adult males used to estimate the prevalence of HIV and AIDS among men who have sex with men in Japan. Sex. Health 8(1), 123-124 (2011).
127. Gorman WL, Gill DS, Scroggs RA, Portner A. The hemagglutininneuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology 175(1), 211-221 (1990). (Pubitemid 20093076)
128. Hara H, Hara H, Hironaka T et al. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors. Hum. Vaccin. 7(6), 639-645 (2011).
129. Dave VP, Allan JE, Slobod KS et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 199(2), 376-383 (1994). (Pubitemid 24168975)
130. Smith FS, Portner A, Leggiadro RJ, Turner EV, Hurwitz JL. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 205(2), 453-461 (1994). (Pubitemid 24371686)
131. Slobod KS, Shenep JL, Luján-Zilbermann J et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22(23-24), 3182-3186 (2004). (Pubitemid 39037223)
132. Matano T, Kobayashi M, Igarashi H et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199(12), 1709-1718 (2004). (Pubitemid 38822004)
133. Tsukamoto T, Yuasa M, Yamamoto H et al. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques. J. Virol. 81(21), 11640-11649 (2007). (Pubitemid 47623796)
134. Tsukamoto T, Takeda A, Yamamoto T, Yamamoto H, Kawada M, Matano T. Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4+ T-cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J. Virol. 83(18), 9339-9346 (2009).
135. Takeda A, Igarashi H, Nakamura H et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replicationdefective Sendai virus vector, in a macaque AIDS model. J. Virol. 77(17), 9710-9715 (2003). (Pubitemid 37011064)
136. Kato M, Igarashi H, Takeda A et al. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 23(24), 3166-3173 (2005).
137. Moriya C, Horiba S, Kurihara K et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies. Vaccine 29(47), 8557-8563 (2011).
138. Shoji M, Yoshizaki S, Mizuguchi H, Okuda K, Shimada M. Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters. PLoS ONE 7(1), e30302 (2012).
139. Wang HB, Kondo A, Yoshida A et al. Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther. 17(1), 4-13 (2010).
140. Pedrana AE, Hellard ME, Wilson K, Guy R, Stoové M. High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia. J. Acquir. Immune Defic. Syndr. 59(1), 94-99 (2012).
141. Chibo D, Birch C. Increasing diversity of human immunodeficiency virus Type 1 subtypes circulating in Australia. AIDS Res. Hum. Retroviruses 28(6), 578-583 (2012).
142. Kelleher AD, Puls RL, Bebbington M et al. A randomized, placebo-controlled Phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 20(2), 294-297 (2006).
143. Buchbinder SP, Mehrotra DV, Duerr A et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008). Major Phase IIB trial of Merck Ad5 HIV vaccine that conferred no protection.
144. Center RJ, Wheatley AK, Campbell SM et al. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 27(47), 6605-6612 (2009).
145. De Rose R, Fernandez CS, Smith MZ et al. Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood. PLoS Pathog. 4(5), e1000055 (2008).
146. Kent SJ, De Rose R, Mokhonov VV et al. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology 374(2), 528-534 (2008).
147. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182(2), 1202-1210 (2009).
148. Zaunders JJ, Munier ML, Seddiki N et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J. Immunol. 183(4), 2827-2836 (2009).
149. Paris RM, Kim JH, Robb ML, Michael NL. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 9(9), 1055-1069 (2010). Excellent review of prime-boost vaccine concepts.
150. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: Lessons learned and the way forward. Curr. Opin. HIV AIDS 5(5), 428-434 (2010).
151. Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482(7383), 89-93 (2012). Heterologous prime-boost regimens with vectors protect against SIV acquisition.
152. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'prime-boost' Phase III trial: Foundations and initial lessons learned from Thailand. AIDS 20(11), 1471-1479 (2006). (Pubitemid 44100207)
153. Lai SK, Hida K, Shukair S et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J. Virol. 83(21), 11196-11200 (2009).
154. Merbah M, Introini A, Fitzgerald W et al. Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am. J. Reprod. Immunol. 65(3), 268-278 (2011).
155. Granich R, Gupta S, Suthar AB et al.; ART in Prevention of HIV and TB Research Writing Group. Antiretroviral therapy in prevention of HIV and TB: Update on current research efforts. Curr. HIV Res. 9(6), 446-469 (2011).
156. Excler JL, Pitisuttithum P, Rerks-Ngarm S et al.; WHO-UNAIDS Regional Consultation. Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J. Trop. Med. Public Health 39(4), 766-784 (2008).
157. Kent SJ, Cooper DA, Chhi Vun M et al.; AIDS Vaccine for Asia Network investigators and supporters. AIDS vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccines. PLoS Med. 7(9), e1000331 (2010). Main paper describing the AIDS vaccine for Asia network.
158. Rerks-Ngarm S, Pitisuttithum P, Ganguly N et al. Defining the objectives of the AIDS vaccine for Asia network: Report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr. Opin. HIV AIDS 5(5), 435-452 (2010).
159. Pitisuttithum P, Rerks-Ngarm S, Chiu J et al.; AIDS Vaccine for Asia Network. Accelerating the development of an AIDS vaccine: The AIDS vaccine for Asia Network (Avan). Southeast Asian J. Trop. Med. Public Health 42(5), 1130-1146 (2011).
160. Koff WC. Accelerating HIV vaccine development. Nature 464(7286), 161-162 (2010).